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Abstract
Humans’ bitter taste perception is mediated by the hTAS2R subfamily of the G protein-coupled membrane receptors
(GPCRs). Structural information on these receptors is currently limited. Here we identify residues involved in the binding
of phenylthiocarbamide (PTC) and in receptor activation in one of the most widely studied hTAS2Rs (hTAS2R38) by
means of structural bioinformatics and molecular docking. The predictions are validated by site-directed mutagenesis
experiments that involve specific residues located in the putative binding site and trans-membrane (TM) helices 6 and 7
putatively involved in receptor activation. Based on our measurements, we suggest that (i) residue N103 participates
actively in PTC binding, in line with previous computational studies. (ii) W99, M100 and S259 contribute to define the
size and shape of the binding cavity. (iii) W99 and M100, along with F255 and V296, play a key role for receptor
activation, providing insights on bitter taste receptor activation not emerging from the previously reported
computational models.
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Introduction
Humans, like other mammals, have evolutionary been prevented
from the ingestion of a large variety of poisonous and toxic
substances by their aversion for bitter tasting food [1-4]. Bitter
substances bind to and are discriminated by a family of roughly,30
bitter taste receptors (TAS2Rs) expressed in taste receptor cells [5–
9]. TAS2Rs belong to the super family of receptors that possess
seven transmembrane helices and interact with intracellular G
proteins and are therefore referred to as heptahelical or G protein-
coupled receptors (GPCRs) [7,9]. Bitter compound binding to its
cognate target TAS2R initiates a downstream cascade of events
inside the cell typical of GPCRs signaling pathways [10]. This
cascade ultimately leads to bitter perception [2].
The knowledge of TAS2Rs’ structural determinants is crucial to
design rationally new chemical taste modifiers. Unfortunately,
GPCRs are notoriously difficult to crystallize and so far only five
independent GPCR X-ray structures have been determined.
These are bovine and squid rhodopsin, turkey beta-1 and human
beta-2 adrenergic receptors, and human adenosine A2 receptor
[11–15].
Hence, insights into the molecular basis of bitter taste sensing
are limited. Two studies on hTAS2R16 and hTAS2R38 relied on
computations only [16,17]. In addition, three experimentally
guided structure-activity studies are available now, which all
addressed hTAS2Rs distantly related to hTAS2R38 [18–20]. First
principle [16] and homology modeling approaches based on
bovine rhodopsin [17] have been used to predict the structure of
the widely studied bitter taste receptor hTAS2R38 [21,22]. Both
works call upon further computational refinement and/or
experimental validations. In fact, the degree of sequence
conservation across the GPCRs superfamily, and the human
bitter taste receptor subfamily (TAS2Rs) in particular, is very low.
In this scenario, experimental validation improves greatly
homology-based models [23,24].
Here, we aim at identifying hTAS2R38 residues involved in
binding to its agonist phenylthiocarbamide (PTC) as well as in
receptor activation. We first use state-of-the-art bioinformatics
approaches based on multiple sequence alignment across the
whole family of GPCRs. However, this procedure is likely not to
be sufficient to identify residues in the binding site as ligand
pockets vary largely in position and orientation across this family
[14]. Addressing this issue is hence aided by predicting the three-
dimensional structure of the receptor, based on the former
alignment and recent structural information on GPCRs along with
massive virtual docking calculations. In fact, homology modeling
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and molecular docking has been shown to guide satisfactorily the
design of site-directed mutagenesis experiments, in spite of the
little power of the structural predictions [25].
The proposed receptor positions are then scrutinized by site-
directed mutagenesis experiments and measurements of receptor
activation by recording intracellular calcium levels following
agonist administration.
Results and Discussion
Screening hTAS2R38 for residues involved in PTC binding
We constructed an ensemble of a few hundred of structural
models of the receptor based on comparative homology
modeling. This was achieved by aligning the hTAS2R38
sequence with those of all GPCRs whose structure has been
solved (Figure S1). Several thousand reiterative virtual docking
calculations followed this step in order to accommodate PTC in
several putative binding sites along the entire modeled structure
of the receptor (Figure S2). Of these, only one pocket is accessible
from the extracellular medium for the PTC agonist (highlighted
with a black arrow in Figure 1A). This cavity is located in a
region equivalent to that occupied by retinal in rhodopsin [11].
The other putative binding cavities were therefore discarded.
According to these predictions, PTC could bind in between TM3
and TM6 helices (Figure 1B). Residues defining the binding
cavity would involve those presumably interacting with PTC:
W99 (upper part of the cavity) and N103 of TM3 (positions 3.32
and 3.36 respectively, according to Ballesteros-Weinstein num-
bering [26]) as well as those located in the close proximity of the
ligand: M100 of TM3 and S259 of TM6 (positions 3.33 and 6.47
respectively) (Figure S3).
The possible impact of specific amino acid residues in positions
predicted to be critical for receptor-agonist interactions has been
subsequently validated by mutagenesis experiments. By tracking
intracellular calcium concentration, we established dose response
curves of receptor activation following PTC administration to cells
that have been previously transfected with DNA for wild-type and
mutant hTAS2R38.
A first group of mutations were designed in order to disrupt
putative interactions between the agonist and the binding pocket
(Figure S3). These involve positions W99 and N103 in TM3.
According to our predictions, mutations of these positions into
valine or alanine would disrupt the hydrophobic interactions
between PTC and the aromatic ring of W99, as well as a potential
H-bond between the ligand and the amino acid side chain of
N103. The collected experimental data reveal that the EC50 values
of N103A and N103V turned out to be significantly larger than
those of WT (t-test has been performed, see Table 1). Moreover,
the N103V mutant was not able to recover the maximal signal
amplitude of WT in the tested range of PTC concentrations
(Figure 2A). These findings suggest that N103 is likely to be
involved in PTC binding, consistent with our predictions. The role
of N103 for binding is also corroborated by the reported models of
the protein [16,17]. On the other hand, W99V and W99A
variants show a remarked increase and decrease, respectively, of
the maximal signal amplitude, compared to WT, while not
deviating significantly from WT in EC50 concentrations
(Figure 2B). We hence suggest that W99 might preferentially be
involved in receptor activation rather than directly in ligand
binding. Also this is consistent with our predictions: W99 not only
points towards the binding site, but also delimits the cavity in its
upper part, being able to interact with specific residues located in
Figure 1. Model of the transmembrane region of hTAS2R38 predicted here. Averaged helix structures are colored as follows: TM1: lemon;
TM2: red; TM3: green; TM4: pink; TM5: cyan; TM6: purple and TM7: gray. (A) The average occupancy of PTC compound during docking calculations is
shown as an orange volume surface. The black arrow highlights the PTC cavity further considered in this work. (B) Schematic representation of the
amino acid positions that are involved in PTC binding to hTAS2R38 receptor and activation as discussed in the text.
doi:10.1371/journal.pone.0012394.g001
Bitter Taste Agonist Binding
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12394
the upper parts of TM2 and TM7 helices (Figure 1). When
different activation states of the receptor are considered in our
models, displacements longer than 3 A˚ are observed between W99
and helices TM2 and TM7. Thus, variations on W99 may modify
the interactions between helices, altering in this way signal
transduction.
A second group of mutations target residues M100 and S259
which are located close to the putative binding cavity, but
predicted not to interact directly with PTC (Figure S3). In previous
reports, however, M100 has been suggested to interact with the
agonist [17]. Hence, variations in these positions may help to
clarify the role of these residues. The mutation of M100 into valine
or alanine should change the hydrophobic interactions between
the aromatic ring of PTC and M100 if present. Changing serine
into valine or alanine should delete the putative H-bond between
the ligand and the side chain of S259.
The EC50 of M100A and S259A (Figure 2C and 2D) are similar
and slightly larger, respectively, than the corresponding value of
WT (Table 1). This suggests that these positions would not play an
active role in direct PTC-receptor interactions. On the other hand,
the maximum activities of M100A and M100V are clearly higher
than the activity of WT (although the elevated maximum activity
observed for M100V compared to wild-type failed to reach
statistical significance because higher concentrations of the agonist
could not be applied), showing that this position may affect
receptor activation. This can be rationalized as a steric effect in
M100 position: when mutated into valine or alanine (smaller in
size), wider conformational changes of the receptor are allowed.
The situation drastically changes with the S259V variant
(Figure 2D). The receptor activation levels are extremely low
even at high PTC concentrations (statistical analysis confirm a
significant difference with respect to background activity of mock
control, and the correct expression levels of the receptor are
verified by immunostaining, see Table 1 and Figure S4). We
suggest that ligand binding and subsequent receptor activation is
very sensitive to the side chain size in this position. According to
our model, S259 delimits the binding cavity in its lower part
(Figure 1). Serine and alanine in the 259 position, which are
similar in size, would keep the shape of the binding cavity. Instead,
valine, which is larger, might disrupt severely the shape of the
binding cavity. Hence, the S259V mutation is expected to impair
the receptor capability to effectively bind PTC and to be activated,
in an indirect fashion. Indeed, the 259 position does not
participate directly to PTC-receptor interactions (see above).
In conclusion, these measurements allow us to suggest that PTC
binds in between TM3 and TM6. In particular N103, belonging to
TM helix 3, interacts directly with PTC. On the other hand, W99
and M100 of TM3, and S259 of TM6 are likely to be located near
the binding cavity and might contribute to define its optimal shape
for binding. Thus, according to our model and measurements,
they do not interact directly with the ligand. All of these
predictions are consistent with the available experimental data
and are in line with previous suggestions [16,17].
Residues involved in receptor activation
Identification of these residues might be assisted by structural
information of bovine rhodopsin [27]: The X-ray structure of this
protein has been determined in two different activation states, in
the presence and absence of the cognate G-protein. The
comparison between the two states shows that TM5, TM6 and
TM7 rearrange largely from one state to the other [27]. In
particular, TM helix 6 tilts around the helical bundle upon G-
protein binding (Figure 3A). The hinge point is given by residue
position 6.43 according to Ballesteros-Weinstein numbering [26].
In the crystal structure of the receptor, this position faces TM helix
7 exactly at the position 7.52. According to our alignment
(Figure 3B), these two positions correspond to F255 and V296,
respectively, in the hTAS2R38 sequence. Thus we hypothesize
that the hydrophobic interaction between F255 and V296 plays a
role for hTAS2R38 receptor activation.
To test this prediction, we determined PTC dose-response
curves for the mutant F255V. Replacing a rather large and
aromatic residue such as phenylalanine with a significantly smaller
and aliphatic residue such as valine would cause a disruption of the
putative interactions between the side chains of F255 and V296.
We then compared the data with those obtained for the natural
hTAS2R38 variants, P49A/A262V/V296I (hTAS2R38-AVI),
and A262V/V296I (hTAS2R38-PVI), which show no or reduced
activity, respectively [24] (Figure S5). Although F255V variant
measurements did not reach saturation, the dose-response profile
of F255V roughly maintains the extrapolated EC50 value with
respect to WT. In light of the fact that the dose-response curve
does not saturate, it remains open if the maximum receptor
activity is increased (Figure 2E). Extrapolating the curve, however,
suggests increased signal amplitude. If this were true, F255 could
indeed play an active role in receptor activation.
In order to check if F255 in TM6 actually interacts with V296
in TM7, we investigated a double cross-mutant, F255V/V296F,
which is expected to recover the original interaction between both
positions. The data in Figure 2E shows indeed that, consistent with
our prediction, the dose-response profile of the double mutant is
identical to the WT. In conclusion, the combined data from our in
silico and in vitro studies suggest that the interaction between F255
and V296 may be critical for receptor activation. This result is
Table 1. Amino acid positions in hTAS2R38 subjected to
mutagenesis and corresponding EC50 values and maximum
activities measured in PTC receptor activation assays.
Variant Location
EC50
( mM)
Max. Activity
(dF/F0)
Expr.
Rate (%)
PAV 3 0.47 31
W99A TM3 4.25 0.25*
(p = 0.019)
35
W99V TM3 2.7 1.12*
(p = 0.0006)
22
M100V TM3 10 1 0.79 15*
(p = 0.014)
M100A TM3 3 1.01*
(p = 0.0005)
15*
(p = 0.012)
N103V TM3 15*
(p,0.0001)
0.09*
(p = 0.0002)
17*
(p = 0.006)
N103A TM3 8*
(p,0.0001)
0.38 14
F255V TM6 4.3 1 0.5 18
F255V/V296F TM6/TM7 2.2 0.5 13*
(p = 0.0003)
S259A TM6 5.4*
(p = 0.004)
0.42 22
S259V TM6 27*
(p,0.0001)
0.04*
(p = 0.0031)
10*
(p = 0.031)
1EC50 extrapolated.
*Statistically significant difference.
Expression rates for receptor variants (expressed in percentage). P-value is
noted for statistically significant different data.
doi:10.1371/journal.pone.0012394.t001
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consistent with the observation that the PVI variant (holding the
V296I mutant) is less sensitive to PTC than the PAV variant
[23](Figure S5).
We thus propose that hTASR38 activation upon PTC binding
is reminiscent of the transition of the G-protein/opsin complex to
free rhodopsin [27], with N103, directly involved in the binding,
W99, M100 and S259 defining the shape of the binding cavity
and, F255 and V296 participating in receptor activation
(Figure 1B). Similar sequences of events also have been suggested
to play a role for activation of all GPCRs [28]. Additional
mutations on the putative G-protein binding region emerging
from the model and in the helices involved in gating (especially
helix TM7) are desirable to complement our knowledge on bitter
taste receptor activation mechanism.
Materials and Methods
Biocomputing
All hTAS2Rs sequences were retrieved from the Uniprot [29]
database using ssearch [30]. They were aligned with PROMALS
Figure 2. Dose-response curves of hTAS2R38 wild type and
mutants after stimulation with increasing PTC concentrations
(0 to 300 mM). Each point corresponds to the mean 6 standard
deviation. The mean is calculated from at least three independent
experiments.
doi:10.1371/journal.pone.0012394.g002
Figure 3. Superposition of transmembranes TM6 and TM7 in
the G-protein free (thin line) and G-protein bound (thick line)
states of bovine rhodopsin (extracted from PDB codes 2I37
and 3DQB respectively). (B) Multiple sequence alignment in TM6
and TM7 region (only opsin and hTAS2R38 sequences are shown).
doi:10.1371/journal.pone.0012394.g003
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[31]. This multiple sequence alignment was then used for the
definition of the Hidden Markov profile (HMM) of hTAS2Rs. The
latter was then funneled through the Hhsearch [32] program to
identify the most plausible homologous structural templates. Such
procedure is currently one of the best ones as evaluated from
CASP7 experiment [33]. The multiple sequence alignment
obtained in this way was used as the reference for the structural
prediction of hTAS2R38 by homology modeling. Homology
models of the receptor are here based on all the solved GPCRs
structures (PDB codes 1U19, 2I37, 2RH1, 2VT4, 2ZTS, 3CAP,
3DQB, 3EML). In fact: (i) the sequence identity between target
and these structural templates turned out to be as low as 13%. (ii)
Some GPCRs have structural features that are distributed over
different crystal structures [34]. (iii) Some GPCRs are in their
activated state (rhodopsin) and others in the inactivated states (the
adrenergic receptor and the adenosine receptor).
The sequence alignment between hTAS2R38 and the eight
structural templates were extracted from the multiple sequence
alignment considering the entire family. We then constructed 50
different conformations of hTAS2R38 (that were obtained with
randomized initial structures and subsequent optimization by
conjugate gradients and simulated annealing) based on each of the
eight structural templates using Modeller9v3 [35]. All the three
dimensional models of hTAS2R38 obtained in this way do not
deviate from currently available experimental geometries (see
Figure S6).
30,000 hTAS2R38/PTC adduct structures were constructed
using Autodock [36–38]. A standard Lamarckian Genetic
Algorithm was used for configurational exploration with a rapid
energy evaluation using grid-based molecular affinity potentials.
Electrostatic, desolvation energies and atom type affinity grid maps
on the receptor were previously calculated with Autogrid [38]. We
generated 100 decoys of PTC compound binding to hTAS2R38
for each of the 50 conformations. The resulting structures were
then clustered according to the three dimensional localization of
the ligand, regardless of the docking energies. Only the clusters in
which the ligand is tightly bound in the active site cavity are
discussed in this work.
Mutant generation and transfection of cells
The 10 hTAS2R38 mutants studied here have been obtained by
mutagenesis PCR using mutagenesis overlapping primers and
hTAS2R38 PAV variant cDNA cloned into a pCDNA5/FRT
plasmid (Invitrogen) as template. The subsequent recombinant
PCR using CMV forward primer, located upstream of the cDNA
sequence, and BGH reverse primer, located downstream of the
cDNA sequence has been performed to fuse the overlapping
mutant fragments. The mutant cDNA sequences have been
digested with EcoRI and NotI restriction enzymes, to be cloned
into a previously digested pCDNA5/FRT. The plasmid presented
an amino terminal export tag corresponding to the first 45 amino
acids of rat somatostatin receptor 3 and a carboxy terminal HSV
tag [39]. The resulting mutant cDNA-constructs were sequenced
to confirm their integrity. Subsequently, the 10 different mutant
variants, as well as two ‘natural’ variants (AVI and PVI) have been
transiently transfected with Lipofectamine2000 in HEK-293T
cells stably expressing the chimeric G protein subunit Ga16gust44,
very effective in coupling with bitter taste receptors [5,40].
Expression assay: immunocytochemistry
HEK-293T cells stably expressing the chimeric G-protein
subunit Ga16gust44 have been seeded on poly-D-lysine coated
coverslips and transfected with the different hTAS2R38 variants.
Cells have been washed with 37uC warm PBS 24 hr after
transfection and incubated on ice for 1 hr. Later, cells have been
incubated on ice with biotin-labeled concanavalin A for plasma
membrane staining and fixed and permeabilized with aceton-
methanol 1:1 solution. Blocking was done using 5% horse serum in
PBS and antibody incubation has been performed over night at
4uC with 1:15000 mouse anti-HSV primary antibody (Novagen).
Secondary antibody incubation included both 1:1000 Streptavidin
Alexa Fluor 633 to label plasma membrane and 1:1000 Alexa488-
conjugated anti-mouse IgG (Molecular Probes) to label receptors
(in 5% horse serum PBS), for 1 hr at room temperature.
Coverslips have been mounted in Dako mounting medium and
analyzed with a Leica confocal microscope.
Functional Assay: Calcium imaging
Calcium imaging assay (that is based on the fluorescence
emission increase of intracellular probes, Fluo4-AM dye, when
bound to Ca2+: Because cytoplasmatic Ca2+ concentration
increases upon GPCRs activation [41], the increase of fluores-
cence of the probes inside cells is associated with activation by
agonist) has been performed 24 hours after transfections, three
times independently for each mutant variant, using a fluorometric
imaging plate reader FLIPR TETRA (Molecular Devices) and
PTC as agonist in a range of 0–300 mM concentration dissolved in
C1 solution. Positive (PAV variant) and negative (mock transfect-
ed) controls have been performed.
Supporting Information
Figure S1 Multiple sequence alignment of available GPCR
crystallographic structures along with human bitter taste receptor
family. (See Methods for computational details).
Found at: doi:10.1371/journal.pone.0012394.s001 (0.98 MB JPG)
Figure S2 Accessibility of PTC compound along different
activation states of hT2R38 as modeled from different structural
templates: (A) antagonist bound state. From left to right:
Adenosine-receptor based model (template PDB code: 3EML),
Beta-1 adrenergic receptor based model (template PDB code:
2VT4) and Beta2 adrenergic receptor based model (template PDB
code: 2RH1). (B) Different activation states of rhodopsin. From left
to right: Ligand free Opsin receptor based model (top) (template
PDB code: 3CAP) and Ligand-free Opsin coupled to G-alpha
peptide receptor based model (bottom) (template PDB code:
3DQB), Inactive Bovine (top) (template PDB code: 1U19) and
Squid (bottom) (template PDB code: 2ZT3) rhodopsin receptor
based model, and active-state MII Bovine rhodopsin receptor
based model (template PDB code: 2I37). Averaged helix structures
and residues belonging to them are colored as follows: TM1:
lemon; TM2: red; TM3: green; TM4: pink; TM5: cyan; TM6:
purple and TM7: gray. The average occupancy of PTC
compound during docking calculations is shown as an orange
volume surface.
Found at: doi:10.1371/journal.pone.0012394.s002 (0.73 MB
PNG)
Figure S3 Representative model of hTAS2R38 receptor bound
to PTC. Putative residues important for binding and receptor
activation are highlighted. The coloring scheme is as in Figure S2.
Ballesteros-Weinstein numbering [25] is indicated in parenthesis.
Found at: doi:10.1371/journal.pone.0012394.s003 (0.66 MB
PNG)
Figure S4 Immunocytochemistry of HEK293 cells expressing
the hTAS2R38 receptor PAV and mutant variants. The
hTAS2R38-expressing cells are shown in green, whereas the cell
surface is labeled in red.
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Found at: doi:10.1371/journal.pone.0012394.s004 (0.44 MB
PNG)
Figure S5 Dose-response curves of hTAS2R38 variants after
stimulation with increasing PTC concentrations (0 to 300 mM).
Each point corresponds to the mean 6 standard deviation. The
mean is calculated on at least three independent experiments
performed in triplicate.
Found at: doi:10.1371/journal.pone.0012394.s005 (0.04 MB
PNG)
Figure S6 3D structure validation of the models. All generated
models have been validated against available experimental
structures by means of PROCHEK server [http://www.ebi.ac.
uk/thornton-srv/software/PROCHECK/]. A summary of the
analysis concerning the Ramachandran angles is shown below. It
indicates that our models do not deviate significantly from the
usual experimental geometries (less than 2% of the amino acids).
Found at: doi:10.1371/journal.pone.0012394.s006 (0.13 MB
PNG)
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